The case centred on claims Sanofi’s epinephrine auto-injector, e-cue, infringed on patents related to the EpiPen injection device Pfizer manufactures for sale in the US by Mylan. Under the terms of the US court settlement Sanofi and its partner, Intelliject, will start selling e-cue after November 15.
“We are pleased with this settlement, and are confident that the EpiPen auto-injector will continue to be a market leader”, Heather Bresch, CEO of Mylan, said.